ContributorsPublishersAdvertisers

#Immunotherapy

GeoVax presents hemorrhagic fever vaccine data at World Vaccine & Immunotherapy Congress

GeoVax Labs (NASDAQ:GOVX) announces data from ongoing studies of its investigational vaccines against hemorrhagic fevers (Sudan, Ebola, & Marburg) at World Vaccine & Immunotherapy Congress, held Nov. 30 – Dec. 2 in San Diego, California. Recent studies in lethal challenge guinea pig models demonstrated that GeoVax vaccines MVA-VLP-SUDV and MVA-VLP-MARV...
SAN DIEGO, CA
Picture for GeoVax presents hemorrhagic fever vaccine data at World Vaccine & Immunotherapy Congress
cancertherapyadvisor.com

Do Antibiotics Affect Outcomes of Immunotherapy in Lung Cancer?

Antibiotic exposure is associated with inferior outcomes of immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC), according to a meta-analysis presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting.1. Prior studies have suggested that the intestinal microbiota may modulate response to ICIs....
CANCER
Picture for Do Antibiotics Affect Outcomes of Immunotherapy in Lung Cancer?
mesothelioma.net

Should Women with Mesothelioma Reconsider Immunotherapy Treatment?

For patients diagnosed with malignant mesothelioma, immunotherapy represents an exciting and promising treatment option. But a new study published in the December 2nd issue of JAMA Network Open is questioning whether women with various types cancer respond differently to the protocol. The study followed male and female advanced melanoma patients treated with the same combination of checkpoint inhibitors. It revealed that the women in the group experienced substantially different side effects and were twice as likely to die.
CANCER
Picture for Should Women with Mesothelioma Reconsider Immunotherapy Treatment?
TRENDING TOPICS
themedicalprogress.com

Dust Mite Immunotherapy Can Help Some With Eczema

Sublingual immunotherapy (SLIT) which uses extracts of house dust mites, showed some benefit in reducing symptoms of Atopic Dermatitis in patients who are sensitive to mites. However, the primary outcome was not significantly improved, as new research shows. The results of a tiny double-blind, randomized study that was placebo-controlled was...
SCIENCE
hospitalhealthcare.com

Allergen immunotherapy effectiveness confirmed in long-term real-world study

Allergen immunotherapy in patients with allergic rhinitis and/or asthma was effective over a 9-year period in a real-world study. The effectiveness of allergen immunotherapy (AIT) in allergic rhinitis (AR) patients both with and without asthma has been confirmed in a 9-year retrospective analysis by researchers from the Paediatric Pulmonology and Allergy, Children’s Doctor Service, Heidelberg, Germany.
SCIENCE
technologynetworks.com

Protein Biomarkers Show Promise in Predicting Patient Response to Cancer Immunotherapies

Cancer immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. However, not all patients respond to immunotherapy, and combination immunotherapies increase cost of treatment and heighten the risk for toxicity-related adverse events. While understanding the complex molecular and cellular...
CANCER
MedPage Today

Immunotherapy Shows Promise for Difficult-to-Treat HRP Ovarian Cancer

A novel immunotherapy provided durable disease control in homologous repair proficient (HRP) ovarian cancer, subgroup data from a small randomized trial showed. After 3 years of follow-up, median overall survival (OS) had yet to be reached in patients who received gemogenovatucel-T (Vigil), but appeared to exceed 41 months, as compared with a median OS of 26.9 months for placebo-treated patients. Median recurrence-free survival (RFS) was almost twice as long with gemogenovatucel-T versus placebo. An analysis of restricted mean survival time (RMST) showed statistically significant improvement in OS and RFS in favor of patients who received the immunotherapy.
CANCER

GeoVax presents COVID-19 vaccine data at World Vaccine & Immunotherapy Congress

GeoVax Labs' (NASDAQ:GOVX) Chief Scientific Officer, Mark J. Newman, discussed the company's vaccine design strategy for developing a universal SARS-CoV-2 vaccine and presented efficacy and immunogenicity data for the Company’s lead and first-generation vaccine candidate, GEO-CM02, which encodes the Spike (S), Membrane (M) and Envelope (E) proteins at the World Vaccine & Immunotherapy Congress, being held November 30 – December 2 in San Diego, California.
SAN DIEGO, CA
targetedonc.com

Roundtable Discussion: Rini Reviews Later-Line Immunotherapy and TKI Combinations in Refractory RCC

Based on the case of a man with metastatic renal cell carcinoma, Brian Rini, MD, and peers discussed later-line immunotherapy and tyrosine kinase inhibitor combination therapies. During a Targeted Oncology Case-Based Roundtable event, Brian Rini, MD, Ingram professor of Medicine, chief of Clinical Trials, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical...
CANCER
cancertherapyadvisor.com

Adding Chemo to Immunotherapy Improves PFS, Not OS, in Non-Small Cell Lung Cancer

Adding chemotherapy to first-line durvalumab plus tremelimumab did not improve overall survival (OS) in patients with stage IV non-small cell lung cancer (NSCLC), according to research published in the Journal of Thoracic Oncology. However, the chemotherapy regimen did improve the overall response rate (ORR) and progression-free survival (PFS) when compared...
CANCER
themedicalprogress.com

ASH Meeting Diversity Inclusion, Immunotherapy and COVID-19

This year, the American Society of Hematology, better known to all as “ASH,” will be hosting its annual meeting in a hybrid format. Content will be presented both live and in person at the Georgia World Congress Center in Atlanta and also online for those who can’t or don’t want to be there in person.
SCIENCE
Newswise

Age-Related Differences in Inflammation May Shed Light on the Limit of Immunotherapies

Newswise — Scientists at the Sbarro Institute for Cancer Research and Molecular Medicine, Center of Biotechnology, located at Temple University’s College of Science and Technology, working with collaborators in Italy, have described the age-related differences in inflammatory response to an emerging immunotherapy treatment for Non-Small-Cell Lung Cancer (NSCLC) called PD-1 blockade. These age-related changes to immune system response, known as immunosenescence, may have implications for the efficacy or the safety of immunotherapies for a variety of conditions and disease.
CANCER
onclive.com

Dr. Qin on Selecting Single-Agent Immunotherapy or Chemoimmunotherapy in NSCLC

Angel Qin, MD, discusses selecting between single-agent immunotherapy or combination chemoimmunotherapy in non–small cell lung cancer. Angel Qin, MD, clinical assistant professor, University of Michigan Health, medical oncologist, Rogel Cancer Center, Michigan Medicine, discusses selecting between single-agent immunotherapy or combination chemoimmunotherapy in non–small cell lung cancer (NSCLC). The PD-L1 expression...
CANCER
mdedge.com

ASH meeting: Diversity, inclusion, immunotherapy, and COVID-19

In 2021, the American Society of Hematology will be hosting its annual meeting in a hybrid format. Content will be presented both live and in person at the Georgia World Congress Center in Atlanta and also online for those who can’t or don’t want to be there in person. Inevitably...
SCIENCE
Daily Gazette

Former Niskayuna interim police chief suing town comptroller

Former Niskayuna interim police chief Fran Wall is suing town Comptroller Ismat Alam for defamation following statements Alam made as part of a workplace complaint. Wall left the department in June after 36 years on the job. Before Wall retired, the town was expected to reprimand Wall after she was investigated by the town’s Hazard Reduction Team for allegedly threatening to kill Alam and harassing her eight separate times.
NISKAYUNA, NY
aacrjournals.org

Augmenting Adoptive T-cell Immunotherapy by Targeting the PD-1/PD-L1 Axis

Cancer immunotherapy utilizing checkpoint blockade antibodies or adoptive cellular therapy (ACT) with tumor-specific T cells has led to unprecedented clinical responses in patients with cancer and has been considered one of the most significant breakthroughs in cancer treatment in the past decade. Nevertheless, many cancers remain refractory to these therapies due to the presence of an immunosuppressive tumor microenvironment. This has led to the innovative idea of combining ACT with checkpoint inhibition. A landmark 2004 study by Blank and colleagues published in Cancer Research was one of the original demonstrations that adoptive transfer of T cells lacking the negative T-cell regulator, PD-1, was able to restore functional T-cell antitumor activity, resulting in rapid regression of established tumors in a preclinical model. This work was instrumental in not only driving clinical studies utilizing checkpoint inhibition but also a new wave of recent trials involving checkpoint blockade in the setting of ACT.
CANCER
Nature.com

Anti-histamines boost immunotherapy

Although immune checkpoint blockade (ICB) therapies have changed cancer care, these agents don’t work for everyone. Writing in Cancer Cell, Li and colleagues provide a potential strategy to increase the efficacy of ICB: anti-histamines. In a retrospective analysis, patients with melanoma who were taking anti-histamines had improved responses to ICBs. In experimental models, histamines push macrophages in the tumour microenvironment to adopt an immunosuppressive ‘M2’ phenotype, providing a potential explanation for their observations.
CANCER
YOU MAY ALSO LIKE